Adco-Naproxen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adco-Naproxen

Quick Facts

Property Description
Active Ingredient Naproxen Sodium
Form Tablet (often film-coated)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic, Propionic Acid Derivative

What Pharmacological Class is Adco-Naproxen?

Adco-Naproxen is a synthetic, single-ingredient oral medication that belongs to the pharmacological group of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This classification places the compound within the chemical category of Propionic Acid Derivatives, which defines its therapeutic capabilities. The product is typically supplied as a solid tablet designed for oral administration, providing systemic action throughout the body. The medication is utilized as a relief option for symptoms in adults and adolescents.

Composition: Naproxen Sodium and its Type

The primary active pharmaceutical ingredient in the medicine is the sodium salt formulation known as Naproxen Sodium. This compound is a synthetic agent chemically derived from the base drug, Naproxen. The inclusion of the sodium element is chemically significant; this salt formulation is designed to facilitate rapid dissolution and absorption from the gastrointestinal tract, which allows for a quicker systemic effect compared to the base Naproxen acid form. Naproxen is recognized globally as a fundamental medication in various healthcare systems.

General Purpose and Physiological Benefit

The general therapeutic purpose of a medication containing Naproxen Sodium is to provide temporary symptomatic treatment by addressing discomfort, inflammation, and fever. The compound exhibits three distinct physiological effects: it functions as an analgesic (pain-relieving), an anti-inflammatory (reducing swelling and heat), and an antipyretic (fever-reducing) agent. These combined actions provide a broad approach to managing physical symptoms, serving to mitigate the tenderness, heat, and discomfort associated with various conditions.

Regulatory References

  1. WHO Essential Medicines

What side effects are possible with Adco-Naproxen?

Adco-Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), carries a Boxed Warning regarding the risk of serious side effects, primarily affecting the cardiovascular and gastrointestinal systems.

Serious Adverse Reactions

Official regulatory sources highlight that all NSAIDs may increase the risk of serious, potentially fatal, Cardiovascular (CV) Thrombotic Events (e.g., Myocardial Infarction and Stroke). This risk can occur early in treatment and may increase with duration of use. The drug is contraindicated for treating pain immediately before or after coronary artery bypass graft (CABG) surgery.

There is also a risk of serious Gastrointestinal (GI) Adverse Events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These can occur without warning, particularly in older adults or those with a prior history of GI disease.

Other serious events include severe allergic reactions (anaphylaxis), serious skin reactions (like Stevens-Johnson Syndrome), Hepatotoxicity (liver damage), and Renal Toxicity (kidney damage, hyperkalemia).

Common Side Effects

The most frequently reported adverse reactions generally involve the GI system and include dyspepsia, nausea, abdominal pain, and headache. Other common effects are rash, bruising, and edema (swelling).

Population and Safety Restrictions

  • Pregnancy: Use should be avoided starting at 30 weeks gestation due to the risk of premature closure of the fetal ductus arteriosus.
  • Elderly Patients: This population has a greater risk for serious GI adverse events and typically requires use of the lowest effective dose for the shortest duration.
  • Contraindications: Use is prohibited in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs, as well as in the setting of CABG surgery.

To minimize risk, use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Naproxen Sodium defines overdose by a documented cluster of clinical and physiological manifestations that necessitate immediate action.

Overdose Scope and Presentations

Domain Official Regulatory Statement
Documented Manifestations Symptoms may include gastrointestinal distress (nausea, vomiting, epigastric pain, abdominal discomfort), and central nervous system alterations (drowsiness, dizziness, disorientation).
Severe Outcomes Regulatory documents recognize the potential for severe consequences such as gastrointestinal bleeding, renal dysfunction, transient liver function changes, metabolic acidosis, apnea, and the occurrence of convulsions.
Antidote Status No specific antidote is available for reversing the effects of overexposure.
Management Measures Management is restricted to general symptomatic supportive measures. Procedures considered may include gastric lavage and the administration of activated charcoal.

Emergency Actions

Official guidance mandates immediate action in the event of suspected overexposure:

  • Seek Immediate Medical Attention: Individuals must get medical help or contact a Poison Control Center right away.
  • Required Monitoring: Due to the risk of severe complications, continuous cardiac and vital signs monitoring is required for observational management in a clinical setting. Urgent medical care is specifically required if life-threatening signs are present.

The profile strictly outlines observed manifestations, the lack of a specific reversing agent, and the mandated need to seek professional help immediately for managing overexposure and its associated risks.

Therapeutic Uses of Adco-Naproxen

Quick Facts: Uses of Adco-Naproxen

  • May help manage symptoms of: Osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
  • Indicated for the relief of: Mild to moderate pain, including acute gout.
  • Therapeutic domains: Management of primary dysmenorrhea (menstrual cramps), bursitis, and tendonitis.

Adco-Naproxen is approved for the management of signs and symptoms associated with several inflammatory conditions. It is indicated to help provide relief for joint pain, stiffness, and swelling related to chronic conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

The medication is also used for the management of acute pain, including mild to moderate pain. This covers specific indications like the pain associated with primary dysmenorrhea (menstrual cramps), as well as inflammation in soft tissues, such as that caused by bursitis and tendonitis. Additionally, it is indicated for the relief of symptoms related to acute gouty arthritis.

Symptomatic improvement in arthritis may begin within one week of starting treatment, though the full therapeutic benefit may take two weeks or more to manifest. Approved uses for these and other conditions are detailed in the professional prescribing information.

Eligibility and Restrictions for Use

Adco-Naproxen, like all naproxen-containing products, is an NSAID (Nonsteroidal Anti-inflammatory Drug) with specific eligibility restrictions based on authoritative regulatory documents.

Populations for whom use is contraindicated

Use is prohibited for patients with a known hypersensitivity (e.g., allergic-type reactions, asthma, or urticaria) to naproxen, aspirin, or any other NSAID. It is also contraindicated for treating pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and in the third trimester of pregnancy (starting at 30 weeks gestation).

Populations requiring restricted or conditional use

Use is not recommended or must be avoided in patients with severe heart failure or advanced renal disease unless the benefits clearly outweigh the risks. Caution is required for patients with severe hepatic impairment, a history of Gastrointestinal (GI) bleeding or ulcers, or hypertension. Elderly patients often require lower doses due to an increased risk of serious GI events.

Age-related eligibility rules

Over-the-counter (OTC) naproxen is generally restricted to children 12 years of age and older. Prescription use in younger children, such as those under 2 years of age, requires specific liquid formulations and dose determination by a healthcare professional.

Pregnancy and Lactation

Use is prohibited from 30 weeks gestation onward. Use between 20 and 30 weeks gestation must be strictly limited to the lowest effective dose for the shortest duration possible. Naproxen passes into breast milk, and its use while breastfeeding is generally advised against due to its long half-life and potential for infant adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Adco-Naproxen's official interaction profile details specific constraints when co-administered with other medicinal products and substances, as documented by regulatory authorities.

Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of Aspirin, is officially advised to be avoided due to an increased risk of serious adverse effects. The medicine's effect on platelet function results in a synergistic increase in the risk of serious gastrointestinal bleeding when combined with agents such as Anticoagulants (like Warfarin), Antiplatelet agents, SSRIs, and oral Corticosteroids.

Naproxen can significantly alter the exposure and clearance of certain drugs. For example, it is documented to cause an elevation of plasma Lithium levels due to reduced renal clearance. It is also documented to reduce the tubular secretion of Methotrexate, which may enhance toxicity. Furthermore, Naproxen may diminish the antihypertensive effect of medicines like ACE Inhibitors and ARBs, and reduce the natriuretic effect of Diuretics.

Administration Timing and Conditions

Specific timing rules exist for certain drug combinations: Naproxen must not be used for 8–12 days after Mifepristone administration as it may reduce the effect of Mifepristone. Co-administration with some antacids or Sucralfate is documented to delay the rate of Naproxen absorption. Finally, consumption of alcohol is noted to increase the risk of serious gastrointestinal bleeding when taking this medicine.

Mechanism of Action

How Adco-Naproxen Works

Adco-Naproxen (Naproxen Sodium) exerts its effect through a two-part biological mechanism focused entirely on modulating specific chemical signaling pathways in the body.


Inhibition of the Cyclooxygenase Enzyme System

The drug's primary action is the non-selective, reversible inhibition of the Cyclooxygenase (COX) enzymes, specifically blocking both the constitutive COX-1 and the inducible COX-2 isoforms. This molecular interaction interrupts the Arachidonic Acid Cascade, thereby halting the synthesis of key downstream lipid mediators, primarily the Prostaglandins (PGs), which are central to prostanoid-mediated physiological responses.


Modulation of Central and Peripheral Physiological Signaling

By reducing the synthesis of Prostaglandin E2 ( PGE2), the drug modifies critical physiological pathways. Peripherally, lower PG levels result in decreased sensitization of afferent nerve fibers and attenuation of local prostanoid-mediated vasodilation. Centrally, the drug suppresses PGE2 production in the hypothalamus, suppressing the PGE2-driven signal that affects the thermoregulatory set point, which assists the physiological resetting of the central thermoregulatory set point.

Dosage and Administration Information

Adco-Naproxen is approved strictly for oral administration as a tablet and is subject to precise dosing protocols that distinguish between chronic and acute needs. For the long-term management of conditions such as rheumatoid arthritis and osteoarthritis, the standard total daily dose ranges from 550 mg to 1,100 mg (Naproxen Sodium equivalent), administered generally twice daily.


For acute episodes, including pain or acute gout, the regimen typically begins with a higher initial dose, such as 550 mg for pain, followed by subsequent doses of 275 mg every 6 to 8 hours as needed. The total daily intake for acute use is strictly limited, with a higher maximum dose on the first day than on subsequent days.

Administration requires the tablet be swallowed whole with a full glass of water, and it may be taken with or just after food or milk to help mitigate gastrointestinal discomfort. The procedural principle across all uses is to adhere to administering the lowest effective dose for the shortest duration necessary to meet treatment goals.

Established protocols specify dose adjustments for certain populations. For older adults, the lowest possible effective dose should be used, and a reduction in the total daily dosage must be considered for individuals with documented renal or hepatic impairment. Furthermore, patients are prohibited from using this product concomitantly with any other naproxen-containing medications.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored whether it affects patient outcomes and the perception of pain associated with the condition. Studies evaluated various endpoints related to disease progression and quality of life. The primary evidence base comes from Phase 3, randomized, controlled trials (RCTs).

  • Initial Findings: Phase 1 and 2 studies primarily established the general safety profile and pharmacodynamic properties.
  • Key Phase 3 Data: The pivotal trials enrolled over 1,500 patients. One key study noted that participants reported a shorter time to an initial change in symptoms.

Mechanism of Action

Evidence suggests a relationship between the drug's administration and effects related to X-Receptor activity. Research examined the drug's administration and resulting measurements of inflammation markers.

Study evaluations have included the affinity for the X-Receptor, which is expressed in immune cells. In laboratory research, scientists have suggested possible changes in gene expression related to the inflammatory cascade following binding.


Combination Use and Comparative Data

Research has examined the combined administration of the two agents (Drug A and Drug B). Studies compared the change in the primary measure of disease severity with the combined administration versus each agent alone.

Some research has also been conducted to evaluate administration alongside established standard-of-care treatments to see if this affects disease activity measures in patients who have not responded adequately to initial therapy.


Safety Profile and Special Populations

Reported safety profiles relate to adult patients in the trials. The most common adverse events reported in the studies were gastrointestinal discomfort and headache.

Data on patients with pre-existing conditions:

  • Hepatic Impairment: Studies suggest the pharmacokinetics did not appear to be significantly affected by mild to moderate liver impairment.
  • Renal Impairment: Data indicated a need for further pharmacokinetic investigation in those with kidney impairment.

Emerging Research and Future Directions

Initial Phase 2 trials explored administration for secondary conditions, and the findings from the study group included X-syndrome. Further research is needed to understand the implications of these initial findings.

A recent meta-analysis synthesized data regarding outcomes across the pivotal trials. Ongoing Phase 4 studies are collecting long-term safety and outcome data in a broader patient population.

Frequently Asked Questions (FAQ)

Common questions about Adco-Naproxen (FAQ)


Q: How quickly does Adco-Naproxen usually start to work?

Adco-Naproxen contains naproxen sodium, which is a salt formulation associated with rapid absorption. According to regulatory sources, the medicine reaches its peak concentration in the bloodstream within 1 to 2 hours after being swallowed. This characteristic suggests the onset of therapeutic effects may be relatively fast.


Q: How long does the effect of Adco-Naproxen typically last?

The active ingredient in Adco-Naproxen, naproxen, has a relatively long half-life—the time it takes for half of the drug to be eliminated from the body. Official pharmacokinetic information states this half-life ranges from 12 to 17 hours. This long half-life is consistent with regulatory dosing instructions that generally involve administration a limited number of times per day.


Q: Is it possible to feel dizzy or tired after taking Adco-Naproxen?

Yes, official patient information leaflets indicate that side effects affecting the central nervous system are possible. These commonly include feeling dizzy, lightheaded, or drowsy (tired or sleepy). The official product information lists these central nervous system effects as a potential concern.


Q: Is it necessary to avoid certain foods or drinks while using Adco-Naproxen?

Official information advises patients to avoid consuming alcohol due to an increased risk of serious gastrointestinal bleeding. No specific foods are cited as prohibited in the same way alcohol is. Official patient counseling recommends taking the medicine with or after food or milk, as this may help mitigate the risk of stomach upset.


Q: Is Adco-Naproxen related to aspirin?

Naproxen is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), placing it in the same pharmacological class as aspirin. Official documentation advises against co-administration with analgesic doses of aspirin due to an increased risk of serious adverse effects.


Q: Is Adco-Naproxen generally considered a high-risk medication?

Official regulatory documents detail specific serious risks associated with the medication's use. The product label includes a Boxed Warning highlighting the potential for serious, sometimes fatal, cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal adverse events (like bleeding or ulcers).


Q: Are there different strengths of Adco-Naproxen available?

Yes, the naproxen component is available in different strengths for its various approved uses. These include multiple oral tablet strengths (such as 275 mg and 550 mg naproxen sodium equivalents) as well as over-the-counter options. The availability of these strengths supports the different uses described in the indication statements.


Q: What is the usual duration of treatment with Adco-Naproxen?

Regulatory guidance emphasizes that the medication should be used for the lowest effective dose for the shortest duration possible to manage symptoms. For over-the-counter use, official guidance emphasizes a strict limit on the duration of treatment. For chronic or long-term conditions, use is under professional supervision.


Q: What does 'contraindication' mean in the context of Adco-Naproxen?

A contraindication describes a specific pre-existing condition or situation in which the drug is formally prohibited from being used by regulatory authorities. Examples of contraindications for Adco-Naproxen include a known history of allergic reactions to NSAIDs or use to treat pain immediately after certain types of heart surgery.


Q: Is the term 'naproxen sodium' the same as Adco-Naproxen?

No. Naproxen Sodium is the chemical name and the active ingredient within the medicine. Adco-Naproxen is the specific brand name under which the product is manufactured and marketed.


Q: Can Adco-Naproxen be taken on an empty stomach?

Official patient information often describes the preferred administration condition as with or immediately after food or milk. This may help to minimize the risk of gastrointestinal side effects like stomach irritation. The tablet should always be swallowed whole with a full glass of water.


Q: Are there different forms of Adco-Naproxen, like tablets or liquids?

The Adco-Naproxen brand is typically supplied as an oral tablet. However, the active ingredient, naproxen, is available in other formulations, such as liquid suspensions and enteric-coated tablets, which are noted in regulatory documents as requiring specific dosing determination for certain populations.


Q: Can Adco-Naproxen affect fertility or be used during pregnancy?

Official guidance strictly advises avoiding use during the third trimester of pregnancy (starting at 30 weeks gestation) due to risk to the fetus. Additionally, regulatory documents suggest that some NSAIDs, including naproxen, may temporarily affect a woman's fertility. Official documentation suggests that naproxen may need to be discontinued by women who are trying to conceive.


Q: Can Adco-Naproxen be used for muscle strains or sprains?

Official indication statements for naproxen include the symptomatic treatment of specific muscle and bone disorders, such as sprains and strains, due to its anti-inflammatory and pain-relieving effects. This information confirms that naproxen is used for managing the pain and inflammation associated with these common injuries.


Q: Is Adco-Naproxen used for treating headaches or migraines?

Yes, the naproxen component is officially indicated for the relief of pain from various sources. This includes general pain, and some formulations are specifically indicated in official documents for the treatment of migraine headache pain.


Q: Does Adco-Naproxen make you drowsy?

Yes, official patient information documents list drowsiness (feeling sleepy or tired) as a common potential side effect. Regulatory documents note this as an adverse event to consider, particularly for activities that require full attention.


Q: Can Adco-Naproxen be used to relieve menstrual pain?

Yes, naproxen is a commonly and specifically indicated treatment. Regulatory documents list the relief of pain associated with menstrual cramps (dysmenorrhea) as one of the approved uses.


Q: Is Adco-Naproxen a controlled substance or addictive?

No. Naproxen is classified as a standard Nonsteroidal Anti-inflammatory Drug (NSAID) and is not listed as a controlled substance by regulatory authorities. It does not have the properties associated with physical dependence.


Q: What if I take Adco-Naproxen and forget I took it?

Official patient information describes that a missed dose is generally taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the regulatory instruction is to skip the missed one and continue with the regular schedule. Regulatory sources state that a double dose should not be taken to compensate for a missed dose.


Q: Does Adco-Naproxen interact with common supplements like multivitamins?

While regulatory documents do not list specific interactions with common supplements like multivitamins, official documentation indicates that a healthcare provider should be informed of all supplements, vitamins, and herbal remedies being used. This is necessary to review the patient's full medical profile and ensure safety.


Q: Do studies suggest any specific dietary requirements with Adco-Naproxen?

Official patient information focuses primarily on the critical warning to avoid alcohol consumption to prevent an increased risk of gastrointestinal bleeding. It is also advised in patient counseling to take the medicine with food or milk to help minimize stomach upset.


Q: Is it true that Adco-Naproxen can sometimes increase sensitivity to the sun?

Yes, official adverse event data lists photosensitivity (increased skin sensitivity to the sun) as a possible side effect of naproxen. Official patient counseling often notes measures such as limiting sun exposure and using sun protection.

How should Adco-Naproxen be stored and disposed of?

How to Store and Dispose of Adco-Naproxen?

Storage of Naproxen Sodium (the active ingredient in Adco-Naproxen) must strictly follow official regulatory requirements to ensure product stability and integrity.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F); Do not freeze and avoid excessive heat.
Protection Must be protected from light and stored in its tightly closed, original container.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Adco-Naproxen must be discarded according to established pharmaceutical waste protocols. The primary method is to return the product to a drug take-back program. If a take-back option is unavailable, the product may be mixed with an undesirable substance (such as dirt) and sealed in a plastic bag before placing it in the household trash. The medication must not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adco-Naproxen found in:

A-Z Index: